<DOC>
	<DOC>NCT00004939</DOC>
	<brief_summary>OBJECTIVES: I. Assess the efficacy of 3,4-diaminopyridine in patients with stable chronic demyelinating polyneuropathy.</brief_summary>
	<brief_title>Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are randomly assigned to oral 3,4-diaminopyridine (3,4-DAP) or placebo administered for 4 days. After a washout of at least 5 days, patients cross to the alternate therapy for 4 days.</detailed_description>
	<mesh_term>Polyradiculoneuropathy</mesh_term>
	<mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Clinical diagnosis of demyelinating neuropathy, i.e.: Hereditary motor and sensory neuropathy type I Chronic inflammatory demyelinating polyneuropathy meeting American Academy of Neurology AIDS Task Force criteria Multifocal motor neuropathy and conduction block Clinically stable for at least 6 months prior to entry Prior/Concurrent Therapy At least 6 months since change in immunosuppressive dose Patient Characteristics Age: 20 to 80 Hepatic: No predisposition to hepatic disease Renal: No predisposition to renal disease Cardiovascular: No predisposition to cardiac disease Other: No other medical condition affecting neuropathy or study evaluation No predisposition to seizures</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>demyelinating neuropathy</keyword>
	<keyword>neurologic and psychiatric disorders</keyword>
	<keyword>rare disease</keyword>
</DOC>